Cediranib has previously been proposed to be causally linked with a reduction in circulating VEGFR1, both in hepatocellular carcinoma (HCC)22 and glioblastoma.23 However, both were uncontrolled single-arm studies. The gene discussed is FLT1; the disease is hepatocellular carcinoma.